PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
42.50%
Some net income increase while GNPX is negative at -0.34%. John Neff would see a short-term edge over the struggling competitor.
0.99%
Some D&A expansion while GNPX is negative at -63.60%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
-10.02%
Both cut yoy SBC, with GNPX at -27.93%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
66.71%
Slight usage while GNPX is negative at -92.06%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
A yoy AP increase while GNPX is negative at -277.72%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-209.52%
Both reduce yoy usage, with GNPX at -79.14%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
100.00%
Well above GNPX's 100.00%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
51.97%
Some CFO growth while GNPX is negative at -77.02%. John Neff would note a short-term liquidity lead over the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.02%
Negative yoy issuance while GNPX is 227.75%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.